153 related articles for article (PubMed ID: 35812182)
1. Hsa_circ_0007312 Promotes Third-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance through Pyroptosis and Apoptosis via the MiR-764/MAPK1 Axis in Lung Adenocarcinoma Cells.
Dai C; Ma Z; Si J; An G; Zhang W; Li S; Ma Y
J Cancer; 2022; 13(9):2798-2809. PubMed ID: 35812182
[No Abstract] [Full Text] [Related]
2. Construction of a circRNA-miRNA-mRNA Regulated Pathway Involved in EGFR-TKI Lung Adenocarcinoma Resistance.
Dai C; Liu B; Li S; Hong Y; Si J; Xiong Y; Wu N; Ma Y
Technol Cancer Res Treat; 2021; 20():15330338211056809. PubMed ID: 34825849
[No Abstract] [Full Text] [Related]
3. Hsa_circ_0005576 promotes osimertinib resistance through the miR-512-5p/IGF1R axis in lung adenocarcinoma cells.
Liu S; Jiang Z; Xiao P; Li X; Chen Y; Tang H; Chai Y; Liu Y; Zhu Z; Xie Q; He W; Ma Y; Jin L; Feng W
Cancer Sci; 2022 Jan; 113(1):79-90. PubMed ID: 34706132
[TBL] [Abstract][Full Text] [Related]
4. The MEK/ERK/miR-21 Signaling Is Critical in Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells.
Huang WC; Yadav VK; Cheng WH; Wang CH; Hsieh MS; Huang TY; Lin SF; Yeh CT; Kuo KT
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885115
[TBL] [Abstract][Full Text] [Related]
5. A Novel Serum Exosomes-Based Biomarker hsa_circ_0002130 Facilitates Osimertinib-Resistance in Non-Small Cell Lung Cancer by Sponging miR-498.
Ma J; Qi G; Li L
Onco Targets Ther; 2020; 13():5293-5307. PubMed ID: 32606748
[TBL] [Abstract][Full Text] [Related]
6. MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.
Yiming R; Takeuchi Y; Nishimura T; Li M; Wang Y; Meguro-Horike M; Kohno T; Horike SI; Nakata A; Gotoh N
Cancer Sci; 2021 Sep; 112(9):3810-3821. PubMed ID: 34145929
[TBL] [Abstract][Full Text] [Related]
7. Circ_0058124 Upregulates MAPK1 Expression to Promote Proliferation, Metastasis and Metabolic Abilities in Thyroid Cancer Through Sponging miR-940.
Sun D; Chen L; Lv H; Gao Y; Liu X; Zhang X
Onco Targets Ther; 2020; 13():1569-1581. PubMed ID: 32110054
[TBL] [Abstract][Full Text] [Related]
8. Circular RNA hsa_circ_0005397 promotes hepatocellular carcinoma progression by regulating the miR-326/PDK2 axis.
Gong J; Du C; Sun N; Xiao X; Wu H
J Gene Med; 2021 Jun; 23(6):e3332. PubMed ID: 33783904
[TBL] [Abstract][Full Text] [Related]
9. Paeonol inhibits the malignancy of Apatinib-resistant gastric cancer cells via LINC00665/miR-665/MAPK1 axis.
Li M; Cai O; Yu Y; Tan S
Phytomedicine; 2022 Feb; 96():153903. PubMed ID: 35026514
[TBL] [Abstract][Full Text] [Related]
10. LncRNA LINC00483 promotes gastric cancer development through regulating MAPK1 expression by sponging miR-490-3p.
Luo M; Liang C
Biol Res; 2020 Apr; 53(1):14. PubMed ID: 32293550
[TBL] [Abstract][Full Text] [Related]
11. Revealing underlying regulatory mechanisms of LINC00313 in Osimertinib-resistant LUAD cells by ceRNA network analysis.
Ding D; Xu C; Zhang J; Zhang Y; Xue L; Song J; Luo Z; Hong X; Wang J; Liang W; Xue X
Transl Oncol; 2024 May; 43():101895. PubMed ID: 38377935
[TBL] [Abstract][Full Text] [Related]
12. Hsa_circ_0101432 promotes the development of hepatocellular carcinoma (HCC) by adsorbing miR-1258 and miR-622.
Zou H; Xu X; Luo L; Zhang Y; Luo L; Yao Y; Xiang G; Huang X; Wang G
Cell Cycle; 2019 Oct; 18(19):2398-2413. PubMed ID: 31095447
[TBL] [Abstract][Full Text] [Related]
13. Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma.
Liu Y; Xiong ZC; Sun X; Sun L; Zhang SL; Ma JT; Han CB
Transl Cancer Res; 2019 Sep; 8(5):2151-2163. PubMed ID: 35116965
[TBL] [Abstract][Full Text] [Related]
14. Circular RNA hsa_circ_0000277 promotes tumor progression and DDP resistance in esophageal squamous cell carcinoma.
Cheng J; Zhang R; Yan M; Li Y
BMC Cancer; 2022 Mar; 22(1):238. PubMed ID: 35241028
[TBL] [Abstract][Full Text] [Related]
15. PIM1 inhibitor synergizes the anti-tumor effect of osimertinib via STAT3 dephosphorylation in EGFR-mutant non-small cell lung cancer.
Sun Z; Zeng L; Zhang M; Zhang Y; Yang N
Ann Transl Med; 2020 Mar; 8(6):366. PubMed ID: 32355810
[TBL] [Abstract][Full Text] [Related]
16.
Pan J; Xing J; Yu H; Wang Z; Wang W; Pan Y
Ann Transl Med; 2023 Mar; 11(6):252. PubMed ID: 37082696
[TBL] [Abstract][Full Text] [Related]
17. Hsa_circ_0000231 knockdown inhibits the glycolysis and progression of colorectal cancer cells by regulating miR-502-5p/MYO6 axis.
Liu Y; Li H; Ye X; Ji A; Fu X; Wu H; Zeng X
World J Surg Oncol; 2020 Sep; 18(1):255. PubMed ID: 32993655
[TBL] [Abstract][Full Text] [Related]
18. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
[TBL] [Abstract][Full Text] [Related]
19. Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance Induced by Membranous/Cytoplasmic/Nuclear Translocation of Epidermal Growth Factor Receptor.
Rong X; Liang Y; Han Q; Zhao Y; Jiang G; Zhang X; Lin X; Liu Y; Zhang Y; Han X; Zhang M; Luo Y; Li P; Wei L; Yan T; Wang E
J Thorac Oncol; 2019 Oct; 14(10):1766-1783. PubMed ID: 31228625
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of circPUM1 impedes cell growth, metastasis and glycolysis of papillary thyroid cancer via enhancing MAPK1 expression by serving as the sponge of miR-21-5p.
Li Y; Qin J; He Z; Cui G; Zhang K; Wu B
Genes Genomics; 2021 Feb; 43(2):141-150. PubMed ID: 33481227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
